Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Serina Therapeutics Receives Second $5 Million Tranche to Strengthen Cash Position Ahead of Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients
Tuesday, February 04, 2025Serina Therapeutics Inca clinicalstage biotechnology company today announced the successful closing of the second million tranche of its previously announced million equity financing with strategic shareholder JuvVentures UK Limited
Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer
Monday, February 03, 2025AstraZenecas Imfinzi durvalumab has been recommended for approval in the European Union EU as monotherapy for the treatment of adults with limitedstage small cell lung cancer LSSCLC whose disease has not progressed following platinumbased chemoradiat...
Hyloris Announces Partnership with Colonis Pharma for XTRAZA in the UK
Monday, February 03, 2025Hyloris Pharmaceuticals SA a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications today announces that an exclusive licence and distribution agreement has been signed with Colonis Pharma Lim...
CHMP recommends subcutaneous RYBREVANT®▼ (amivantamab) for the treatment of patients with advanced EGFR-mutated non-small cell lung cancer
Monday, February 03, 2025JanssenCilag International NV a Johnson Johnson company today announced that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA has recommended an extension of marketing authorisation for a subcutaneous SC f...
RYSTIGGO[®]▼(rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods
Saturday, February 01, 2025UCB a global biopharmaceutical company today announced the CHMP Committee for Medicinal Products for Human Use has issued a positive opinion for the selfadministration of RYSTIGGO rozanolixizumab via an infusion syringe pump or a new manual push syri...
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Friday, January 31, 2025Vertex Pharmaceuticals Incorporatedtoday announced that the US Food and Drug Administration FDA has approved JOURNAVX suzetrigine an oral nonopioid highly selective NaV pain signal inhibitor for the treatment of adults with moderatetosevere acute pai...
Mitsubishi Tanabe Pharma America Announces Real-World Data Analysis of Disease Progression with RADICAVA® (edaravone) in ALS
Friday, January 31, 2025Mitsubishi Tanabe Pharma America Inc MTPA today announced the publication of a retrospective analysis of realworld data in the Journal of Comparative Effectiveness Research JCER The study suggests that in patients with amyotrophic lateral sclerosis A...
OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy
Thursday, January 30, 2025OSE Immunotherapeutics SA and Scienta Lab a leader in Artificial Intelligence AIdriven precision immunology announce a strategic collaboration to harness Scienta Labs advanced AI platform for modeling inflammatory diseases and identifying predictive...
Dewpoint Therapeutics Announces DPTX3496 as a Development Candidate for the Treatment of Colorectal, Breast, and Lung Cancers
Thursday, January 30, 2025Dewpoint Therapeutics Inc the leading biotechnology company in transforming condensate biology into medicine announced today the nomination of a second development candidate DC DPTX DPTX is an oral small molecule condensate modulator cmod targeting...
Curium Further Expands European Availability of PYLCLARI – an Innovative 18F-PSMA PET Radiopharmaceutical Indicated in Patients with Prostate Cancer
Wednesday, January 29, 2025Curium a world leader in nuclear medicine today announced that in Estonia Finland Latvia and Sweden PYLCLARI is now available for patients with prostate cancer PYLCLARI INN Piflufolastat F also known as FDCFPyL is indicated for the detection of prost...
